IL132240A0 - Anti-vegf antibodies - Google Patents

Anti-vegf antibodies

Info

Publication number
IL132240A0
IL132240A0 IL13224098A IL13224098A IL132240A0 IL 132240 A0 IL132240 A0 IL 132240A0 IL 13224098 A IL13224098 A IL 13224098A IL 13224098 A IL13224098 A IL 13224098A IL 132240 A0 IL132240 A0 IL 132240A0
Authority
IL
Israel
Prior art keywords
vegf
vegf antibodies
vitro
antibodies
inhobit
Prior art date
Application number
IL13224098A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27125626&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL132240(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/908,469 external-priority patent/US6884879B1/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IL132240A0 publication Critical patent/IL132240A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Air Bags (AREA)
  • Steering Control In Accordance With Driving Conditions (AREA)
IL13224098A 1997-04-07 1998-04-03 Anti-vegf antibodies IL132240A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83350497A 1997-04-07 1997-04-07
US08/908,469 US6884879B1 (en) 1997-04-07 1997-08-06 Anti-VEGF antibodies
PCT/US1998/006604 WO1998045331A2 (en) 1997-04-07 1998-04-03 Anti-vegf antibodies

Publications (1)

Publication Number Publication Date
IL132240A0 true IL132240A0 (en) 2001-03-19

Family

ID=27125626

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13224098A IL132240A0 (en) 1997-04-07 1998-04-03 Anti-vegf antibodies

Country Status (25)

Country Link
US (2) US7060269B1 (OSRAM)
EP (4) EP1787999B1 (OSRAM)
JP (1) JP3957765B2 (OSRAM)
KR (2) KR100816621B1 (OSRAM)
CN (1) CN100480269C (OSRAM)
AT (2) ATE349470T1 (OSRAM)
AU (1) AU743758B2 (OSRAM)
BR (1) BRPI9809387B8 (OSRAM)
CA (1) CA2286330C (OSRAM)
CY (3) CY2005008I2 (OSRAM)
DE (5) DE69836729T2 (OSRAM)
DK (2) DK1325932T5 (OSRAM)
ES (2) ES2273415T3 (OSRAM)
FR (2) FR05C0020I2 (OSRAM)
GE (1) GEP20105118B (OSRAM)
IL (1) IL132240A0 (OSRAM)
LT (1) LTPA2005005I1 (OSRAM)
LU (2) LU91167I2 (OSRAM)
NL (2) NL300193I2 (OSRAM)
NO (3) NO324264B1 (OSRAM)
NZ (1) NZ500078A (OSRAM)
PT (1) PT1325932E (OSRAM)
SI (1) SI1325932T1 (OSRAM)
TR (1) TR199903123T2 (OSRAM)
WO (1) WO1998045331A2 (OSRAM)

Families Citing this family (508)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US6361974B1 (en) 1995-12-07 2002-03-26 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
US5830696A (en) 1996-12-05 1998-11-03 Diversa Corporation Directed evolution of thermophilic enzymes
US7018793B1 (en) 1995-12-07 2006-03-28 Diversa Corporation Combinatorial screening of mixed populations of organisms
US6562594B1 (en) 1999-09-29 2003-05-13 Diversa Corporation Saturation mutagenesis in directed evolution
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
US6939689B2 (en) 1995-12-07 2005-09-06 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
US6358709B1 (en) 1995-12-07 2002-03-19 Diversa Corporation End selection in directed evolution
US6352842B1 (en) 1995-12-07 2002-03-05 Diversa Corporation Exonucease-mediated gene assembly in directed evolution
US6740506B2 (en) 1995-12-07 2004-05-25 Diversa Corporation End selection in directed evolution
US6238884B1 (en) 1995-12-07 2001-05-29 Diversa Corporation End selection in directed evolution
US6713279B1 (en) 1995-12-07 2004-03-30 Diversa Corporation Non-stochastic generation of genetic vaccines and enzymes
US6171820B1 (en) * 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
JP3521382B2 (ja) 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
SI1325932T1 (OSRAM) 1997-04-07 2005-08-31 Genentech Inc
US20070059302A1 (en) * 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
US20020032315A1 (en) * 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US6864227B1 (en) 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
US6887674B1 (en) 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
JP2002530081A (ja) 1998-11-18 2002-09-17 ジェネンテック・インコーポレーテッド 親抗体より高度な結合親和性を持つ抗体変異体
EP1950300A3 (en) 1998-11-18 2011-03-23 Genentech, Inc. Antibody variants with higher binding affinity compared to parent antibodies
WO2000034337A1 (en) * 1998-12-10 2000-06-15 Tsukuba Research Laboratory, Toagosei Co., Ltd. Humanized monoclonal antibodies against vascular endothelial cell growth factor
ATE300957T1 (de) * 1998-12-22 2005-08-15 Genentech Inc Antagonisten von vaskular-endothelialen zellwachstumsfaktoren und ihre anwendung
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
WO2000064946A2 (en) 1999-04-28 2000-11-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
EP1203026A4 (en) * 1999-07-29 2005-03-16 Dyax Corp FRACTIONS BINDING FIBRIN
JP4210454B2 (ja) 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
EP1757311B1 (en) 1999-12-24 2009-02-11 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
CA2921260A1 (en) 1999-12-24 2001-06-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
CA2648051A1 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
DK2042597T3 (da) 2000-06-23 2014-08-11 Genentech Inc Sammensætninger og fremgangsmåder til diagnose og behandling af sygdomme, der involverer angiogenese
US6902718B2 (en) 2000-10-24 2005-06-07 Diatide, Inc. Stabilization of radiopharmaceutical compositions using hydrophilic thioethers
US6989138B2 (en) 2000-10-24 2006-01-24 Diatide, Inc. Stabilization of radiopharmaceutical compositions using hydrophilic thioethers and hydrophilic 6-hydroxy chromans
JP4212278B2 (ja) 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
US7667004B2 (en) 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
TWI284539B (en) 2001-07-30 2007-08-01 Epix Pharm Inc A method for making a magnetic resonance (MR) imaging agent, a MR imaging contrast agent, a method for altering stability of a peptide and a modified peptide
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
PL213948B1 (pl) * 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20030190705A1 (en) * 2001-10-29 2003-10-09 Sunol Molecular Corporation Method of humanizing immune system molecules
EP2048154B2 (en) 2002-02-05 2015-06-03 Genentech, Inc. Protein purification
WO2003102132A2 (en) 2002-04-26 2003-12-11 Genetech, Inc. Non-affinity purification of proteins
NZ571508A (en) * 2002-05-24 2010-05-28 Schering Corp Neutralizing human anti-IGFR antibody
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
NZ574146A (en) 2002-07-15 2010-05-28 Univ Texas Peptides binding to phosphatidylethanolamine and their use in treating viral infections
PT1523496E (pt) 2002-07-18 2011-09-29 Merus B V Produção de misturas de anticorpos de forma recombinante
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
WO2004065417A2 (en) * 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
EP2192172B1 (en) 2003-02-03 2014-12-03 iBio, Inc. System for expression of genes in plants
WO2004080418A2 (en) 2003-03-12 2004-09-23 Vasgene Therapeutics, Inc. Nucleic acid compounds for inhibiting angiogenesis and tumor growth
US7381410B2 (en) 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
US8431396B2 (en) 2003-03-21 2013-04-30 The Cleveland Clinic Foundation Anti-angiogenic peptides
ES2427641T3 (es) 2003-05-22 2013-10-31 Ibio, Inc. Molécula vehículo recombinante para la expresión, el suministro y la purificación de polipéptidos diana
US20050186208A1 (en) 2003-05-30 2005-08-25 Genentech, Inc. Treatment with anti-VEGF antibodies
EP1639009B1 (en) 2003-05-30 2013-02-27 Merus B.V. Fab library for the preparation of a mixture of antibodies
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
CA2531595C (en) 2003-07-28 2015-12-08 Genentech, Inc. Reducing protein a leaching during protein a affinity chromatography
EP1664115A2 (en) * 2003-08-01 2006-06-07 Genentech, Inc. Antibody cdr polypeptide sequences with restricted diversity
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
NZ592039A (en) 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
FR2859725B1 (fr) * 2003-09-16 2006-03-10 Neovacs Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine
US9247900B2 (en) 2004-07-13 2016-02-02 Dexcom, Inc. Analyte sensor
CA2554054C (en) 2004-01-20 2013-06-04 Merus B.V. Mixtures of binding proteins
EP3653641A1 (en) 2004-02-19 2020-05-20 Genentech, Inc. Cdr-repaired antibodies
NZ549787A (en) 2004-03-12 2010-05-28 Vasgene Therapeutics Inc Antibodies binding to EphB4 for inhibiting angiogenesis and tumor growth
KR20070034465A (ko) 2004-03-12 2007-03-28 바스진 테라퓨틱스, 인크. 혈관형성 및 종양 성장을 억제하기 위한 폴리펩티드 화합물
JP2008500830A (ja) 2004-06-01 2008-01-17 ドマンティス リミテッド 増加した血清半減期を有する二重特異性融合抗体
US7946984B2 (en) 2004-07-13 2011-05-24 Dexcom, Inc. Transcutaneous analyte sensor
US20060270922A1 (en) 2004-07-13 2006-11-30 Brauker James H Analyte sensor
US8604185B2 (en) 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
EP1771474B1 (en) * 2004-07-20 2010-01-27 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
BRPI0513601A (pt) 2004-07-23 2008-05-13 Genentech Inc métodos de produção de cristais de anticorpo ou seu fragmento, composições, formulação, cristal de anticorpo ou seu fragmento, método de tratamento e métodos de produção de cristais e de gel de proteìna de anticorpo ou seu fragmento
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
AU2005286662B2 (en) 2004-09-23 2011-10-06 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
PL1802334T3 (pl) * 2004-10-21 2013-01-31 Genentech Inc Sposób leczenia wewnątrzgałkowych chorób neowaskularnych
EP2290087A3 (en) 2004-12-22 2011-06-15 Genentech, Inc. Methods for producing soluble multi-membrane-spanning proteins
EP1833512A1 (en) * 2005-01-06 2007-09-19 GE Healthcare AS Optical imaging
US20070166388A1 (en) 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
DK2586459T3 (en) 2005-03-25 2017-09-11 Regeneron Pharma VEGF antagonist formulations
US20060233810A1 (en) * 2005-04-15 2006-10-19 Yaolin Wang Methods and compositions for treating or preventing cancer
EP1895947A2 (en) * 2005-06-17 2008-03-12 Abbott Laboratories Improved method of treating degenerative spinal disorders
USRE47223E1 (en) 2005-06-20 2019-02-05 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
PL2135881T3 (pl) * 2005-06-20 2012-02-29 Genentech Inc Przeciwciała wiążące się z antygenem TAT10772 związanym z nowotworem, do diagnozowania i leczenia nowotworu
KR101446025B1 (ko) 2005-08-03 2014-10-01 아이바이오, 인크. 면역글로불린의 생산을 위한 조성물 및 방법
PL3311805T3 (pl) 2005-08-31 2020-07-27 Abraxis Bioscience, Llc Kompozycje zawierające słabo rozpuszczalne w wodzie środki farmaceutyczne i środki przeciwdrobnoustrojowe
UA96139C2 (uk) 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
KR100877824B1 (ko) 2005-11-11 2009-01-12 한국생명공학연구원 Ｅ2ｅｐｆ ｕｃｐ-ｖｈｌ 상호작용 및 그 용도
JP5199108B2 (ja) * 2005-11-14 2013-05-15 ユニヴァーシティー オブ サザン カリフォルニア インテグリン結合小分子
TW200804425A (en) * 2005-12-06 2008-01-16 Domantis Ltd Ligands that have binding specificity for EGFR and/or VEGF and methods of use therefor
PL1962895T3 (pl) † 2005-12-16 2013-06-28 Regeneron Pharma Terapeutyczne zastosowanie antagonisty dii4 oraz inhibitora vegf do inhibicji wzrostu nowotworów
TWI596111B (zh) 2006-01-05 2017-08-21 建南德克公司 抗ｅｐｈｂ４抗體及使用該抗體之方法
ZA200806187B (en) 2006-01-20 2009-10-28 Genentech Inc Anti-EphrinB2 antibodies and methods using same
CA2642054C (en) 2006-02-13 2017-11-21 Fraunhofer Usa, Inc. Influenza antigens, vaccine compositions, and related methods
AR059851A1 (es) 2006-03-16 2008-04-30 Genentech Inc Anticuerpos de la egfl7 y metodos de uso
WO2008060645A2 (en) 2006-03-21 2008-05-22 Genentech, Inc. Combinatorial therapy involving alpha5beta1 antagonists
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
CN101405030B (zh) * 2006-03-22 2013-03-13 霍夫曼-拉罗奇有限公司 针对血管内皮生长因子的抗体和针对人表皮生长因子2型受体的抗体在制备治疗肿瘤的试剂盒中的应用
EP1999151A2 (en) * 2006-03-29 2008-12-10 Genentech, Inc. Diagnostics and treatments for tumors
ES2828739T3 (es) 2006-04-07 2021-05-27 Aerpio Pharmaceuticals Inc Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos
SG175615A1 (en) 2006-06-06 2011-11-28 Genentech Inc Anti-dll4 antibodies and methods using same
WO2007143689A2 (en) * 2006-06-06 2007-12-13 Genentech, Inc. Compositions and methods for modulating vascular development
RU2432155C3 (ru) 2006-06-16 2017-11-17 Ридженерон Фармасьютикалз, Инк. Составы антагониста vegf, подходящие для интравитреального введения
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
WO2008011513A2 (en) 2006-07-19 2008-01-24 The Cleveland Clinic Foundation Compounds and methods of modulating angiogenesis
CN100448892C (zh) * 2006-08-02 2009-01-07 中国人民解放军军事医学科学院基础医学研究所 抗肿瘤血管内皮生长因子受体vegf－r2抗原及其编码基因与应用
EP2441472B1 (en) 2006-08-21 2015-06-10 F. Hoffmann-La Roche AG Tumor therapy with an anti-VEGF antibody
ME02371B (me) 2006-09-29 2016-06-20 Oncomed Pharm Inc Sastojci i postupci za dijagnstikovanje i tretman raka
ZA200901518B (en) 2006-10-04 2010-05-26 Genentech Inc Elisa for VEGF
US20110076279A1 (en) * 2006-10-20 2011-03-31 Schering Corporation Fully human anti-vegf antibodies and methods of using
SG10201503407WA (en) 2006-12-19 2015-06-29 Genentech Inc Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
WO2008079280A1 (en) 2006-12-21 2008-07-03 Millipore Corporation Purification of proteins
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
EP2377527B1 (en) 2007-01-22 2013-07-17 Genentech, Inc. Polyelectrolyte precipitation and purification of antibodies
WO2008091222A1 (en) * 2007-01-26 2008-07-31 Bioinvent International Ab Dll4 signaling inhibitors and uses thereof
EP2125896A2 (en) 2007-02-09 2009-12-02 Genetech, Inc. Anti-robo4 antibodies and uses therefor
CL2008001334A1 (es) 2007-05-08 2008-09-22 Genentech Inc Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer.
KR101520115B1 (ko) 2007-05-17 2015-05-13 제넨테크, 인크. 항-뉴로필린 ２ 항체에 의한 종양 전이의 억제
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
CA3113365A1 (en) 2007-07-09 2009-01-15 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
WO2009009759A2 (en) 2007-07-11 2009-01-15 Fraunhofer Usa, Inc. Yersinia pestis antigens, vaccine compositions, and related methods
JP5749009B2 (ja) 2007-08-13 2015-07-15 バスジーン セラピューティクス, インコーポレイテッドVasgenetherapeutics, Inc. ＥｐｈＢ４に結合するヒト化抗体を利用する癌治療剤
EP2190861A4 (en) 2007-08-22 2011-03-30 Univ California ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
RU2498991C2 (ru) 2007-10-30 2013-11-20 Дженентек, Инк. Очистка антител с помощью катионообменной хроматографии
AR070032A1 (es) 2007-11-09 2010-03-10 Genentech Inc Composiciones y metodos de uso de antagonistas quinasa-1 similar al receptor de la activina (alk-1)
EP2614837A1 (en) 2007-11-09 2013-07-17 Affitech Research AS Anti-VEGF antibody compositions and methods
AR069501A1 (es) 2007-11-30 2010-01-27 Genentech Inc Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
KR20160125535A (ko) 2008-03-18 2016-10-31 제넨테크, 인크. 항-ｈｅｒ２ 항체-약물 접합체와 화학요법제의 병용물, 및 사용 방법
EP2604279A1 (en) * 2008-03-27 2013-06-19 ZymoGenetics, Inc. Compositions and methods for inhibiting PDGFRBETA and VEGF-A
EP2280997A2 (en) * 2008-04-18 2011-02-09 Xencor, Inc. Human equivalent monoclonal antibodies engineered from nonhuman variable regions
SG190572A1 (en) 2008-04-29 2013-06-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
SG191639A1 (en) 2008-06-03 2013-07-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
PE20100054A1 (es) 2008-06-03 2010-03-03 Abbott Lab Inmunoglobulina con dominio variable dual
WO2009151514A1 (en) 2008-06-11 2009-12-17 Millipore Corporation Stirred tank bioreactor
LT3216803T (lt) 2008-06-25 2020-06-10 Novartis Ag Stabilūs ir tirpūs antikūnai, slopinantys vegf
MX2010014574A (es) * 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
US20100029491A1 (en) * 2008-07-11 2010-02-04 Maike Schmidt Methods and compositions for diagnostic use for tumor treatment
WO2010010153A1 (en) 2008-07-23 2010-01-28 F. Hoffmann-La Roche Ag Identification of subjects being susceptible to anti-angiogenesis therapy
HUE047316T2 (hu) 2008-08-14 2020-04-28 Genentech Inc Eljárások szennyezés eltávolítására indigén fehérjekiszorításos ioncserés membrán kromatográfia alkalmazásával
EP2321433A2 (en) * 2008-08-29 2011-05-18 F. Hoffmann-La Roche AG Diagnostics and treatments for vegf-independent tumors
US20110318360A1 (en) 2008-09-05 2011-12-29 Duke University Anti-lipid antibodies
EP2334323A2 (en) 2008-09-10 2011-06-22 F. Hoffmann-La Roche AG Compositions and methods for the prevention of oxidative degradation of proteins
WO2010037046A1 (en) 2008-09-28 2010-04-01 Fraunhofer Usa, Inc. Humanized neuraminidase antibody and methods of use thereof
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
PL2352521T3 (pl) 2008-10-14 2021-03-08 Genentech, Inc. Warianty immunoglobuliny i ich zastosowania
WO2010060748A1 (en) 2008-11-03 2010-06-03 Molecular Partners Ag Binding proteins inhibiting the vegf-a receptor interaction
EP2540843B1 (en) 2008-11-05 2014-07-02 Genentech, Inc. Genetic polymorphisms in age-related macular degeneration
KR101807319B1 (ko) 2008-11-22 2017-12-11 제넨테크, 인크. 유방암의 치료를 위한, 화학요법과 조합된 항-ｖｅｇｆ 항체의 용도
CN105037535A (zh) 2008-12-16 2015-11-11 Emd密理博公司 搅拌槽反应器及方法
US20110020327A1 (en) 2008-12-16 2011-01-27 Millipore Corporation Purification of proteins
SG10201604988YA (en) 2008-12-23 2016-07-28 Genentech Inc Methods and compositions for diagnostic use in cancer patients
BRPI1006141B8 (pt) 2009-01-12 2021-05-25 Cytomx Therapeutics Llc composições de anticorpo modificado, métodos para preparar e usar as mesmas
WO2010081838A2 (en) 2009-01-14 2010-07-22 Novartis Ag Sterile prefilled container
JP2012517434A (ja) 2009-02-06 2012-08-02 ザ ジェネラル ホスピタル コーポレイション 血管病変を治療する方法
CN102481341B (zh) 2009-02-23 2017-05-17 希托马克斯医疗有限公司 蛋白原及其使用方法
EP2400992B1 (en) 2009-02-27 2015-07-22 Genentech, Inc. Methods and compositions for protein labelling
KR101739598B1 (ko) 2009-03-13 2017-06-08 아브락시스 바이오사이언스, 엘엘씨 티오콜키신 유도체와의 조합 요법
AR075925A1 (es) 2009-03-25 2011-05-04 Genentech Inc Anticuerpos anti-alfa5beta1 (alfa5beta1: glicoproteina integrina) y sus usos
CN102369215B (zh) 2009-04-02 2015-01-21 罗切格利卡特公司 包含全长抗体和单链Fab片段的多特异性抗体
ES2537100T3 (es) 2009-04-07 2015-06-02 Roche Glycart Ag Anticuerpos biespecíficos trivalentes
JP5795759B2 (ja) * 2009-04-16 2015-10-14 アッヴィ・バイオセラピューティクス・インコーポレイテッド 抗ＴＮＦ−α抗体およびその用途
BRPI1006438A2 (pt) * 2009-04-20 2016-09-27 Genentech Inc terapia adjuvante de cancer
CA2759233C (en) 2009-04-27 2019-07-16 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
US9309325B2 (en) 2009-05-07 2016-04-12 The Regents Of The University Of California Antibodies and methods of use thereof
CA2665956A1 (en) * 2009-05-07 2010-11-07 Samir Patel Combination treatment for ocular diseases
CA2760246A1 (en) 2009-05-08 2010-11-11 Weilan Ye Humanized anti-egfl7 antibodies and methods using same
MX353352B (es) 2009-05-08 2018-01-10 Vaccinex Inc Anticuerpos anti-cd100 y metodos para su uso.
AU2010262087B9 (en) 2009-06-15 2015-07-30 Icon Genetics Gmbh Nicotiana benthamiana plants deficient in xylosyltransferase activity
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
WO2011008696A2 (en) 2009-07-13 2011-01-20 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
AR078060A1 (es) 2009-07-14 2011-10-12 Novartis Ag Descontaminacion de superficie de contenedores previamente llenados en empaque secundario
AR077595A1 (es) 2009-07-27 2011-09-07 Genentech Inc Tratamientos de combinacion
NZ597531A (en) * 2009-07-31 2014-05-30 Genentech Inc Inhibition of tumor metastasis using bv8- or g-csf-antagonists
IL264336B2 (en) 2009-08-11 2024-02-01 Genentech Inc Production of proteins in cell culture medium without glutamine
MX2012001716A (es) 2009-08-14 2012-04-02 Genentech Inc Marcadores biologicos para monitorizar la respuesta del paciente a los antagonistas vegf.
CA2771086A1 (en) 2009-08-15 2011-02-24 Genentech, Inc. Anti-angiogenesis therapy for the treatment of previously treated breast cancer
CN102686738A (zh) 2009-09-01 2012-09-19 弗·哈夫曼-拉罗切有限公司 通过改进的a蛋白洗脱增强的蛋白质纯化
WO2011028642A1 (en) 2009-09-04 2011-03-10 University Of Louisville Research Foundation, Inc. Genetic determinants of prostate cancer risk
AU2010292060A1 (en) 2009-09-11 2012-04-12 Genentech, Inc. Method to identify a patient with an increased likelihood of responding to an anti-cancer agent
JP6091894B2 (ja) 2009-09-16 2017-03-15 ジェネンテック， インコーポレイテッド コイルドコイルおよび／またはテザー含有タンパク質複合体およびその使用
KR101557545B1 (ko) 2009-09-17 2015-10-06 에프. 호프만-라 로슈 아게 암 환자에서 진단 용도를 위한 방법 및 조성물
US8784819B2 (en) 2009-09-29 2014-07-22 Ibio Inc. Influenza hemagglutinin antibodies, compositions and related methods
US8883145B2 (en) 2009-10-16 2014-11-11 Oncomed Pharmaceuticals, Inc. Methods of treatment with DLL4 antagonists and an anti-hypertensive agent
MX2012004306A (es) 2009-10-21 2012-04-30 Genentech Inc Polimorfismos geneticos en degeneracion macular relacionada con la edad.
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
JP5818805B2 (ja) 2009-12-11 2015-11-18 ジェネンテック， インコーポレイテッド 抗ｖｅｇｆ−ｃ抗体及びその使用方法
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
SG181834A1 (en) 2009-12-21 2012-07-30 Genentech Inc Antibody formulation
HUE027713T2 (en) 2009-12-23 2016-10-28 Hoffmann La Roche Anti-BV8 antibodies and their use
US20130178608A1 (en) 2009-12-29 2013-07-11 Samir Kulkarni Protein purification by ion exchange
US20120309056A1 (en) 2010-02-04 2012-12-06 Leon Arnaud Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells
AR080244A1 (es) 2010-02-23 2012-03-21 Genentech Inc Terapia anti-angiogenesis para el tratamiento del cancer ovarico
CN103124564B (zh) 2010-03-22 2016-11-09 弗·哈夫曼-拉罗切有限公司 对于稳定含有蛋白质的制剂有用的组合物和方法
AR080793A1 (es) 2010-03-26 2012-05-09 Roche Glycart Ag Anticuerpos biespecificos
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
CN105147613A (zh) 2010-03-29 2015-12-16 阿布拉科斯生物科学有限公司 增强药物递送和治疗剂有效性的方法
RU2016119999A (ru) 2010-03-29 2018-11-08 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечения онкологических заболеваний
EP2560641A2 (en) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
WO2011139718A1 (en) 2010-05-03 2011-11-10 Genentech, Inc. Compositions and methods useful for reducing the viscosity of protein-containing formulations
DK2571903T3 (da) 2010-05-17 2019-11-04 Emd Millipore Corp Polymerer, der reagerer på stimuli, til oprensning af biomolekyler
BR112012030197A2 (pt) 2010-05-28 2015-09-29 Genentech Inc diminuição do nível de lactato e aumento da produção de poliptídeo por subregulação da expressão de lactato desidrogenase e piruvato desidrogenase cinase.
WO2011153224A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
WO2011153243A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Anti-angiogenesis therapy for treating gastric cancer
EP2575804A4 (en) 2010-06-04 2013-10-23 Abraxis Bioscience Llc METHOD FOR THE TREATMENT OF PANCREASCRE
ES2751381T3 (es) 2010-06-24 2020-03-31 Hoffmann La Roche Composiciones y procedimientos que contienen alquilglucósidos para estabilizar formulaciones que contienen proteínas
CA2799472A1 (en) 2010-07-02 2012-01-05 Genentech, Inc. Treatment of vascularized pigment epithelial detachment with anti-vegf therapy
NZ605449A (en) 2010-07-09 2015-03-27 Genentech Inc Anti-neuropilin antibodies and methods of use
AU2011281702A1 (en) 2010-07-19 2013-01-31 F. Hoffmann-La Roche Ag Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
EP2596362A1 (en) 2010-07-19 2013-05-29 F. Hoffmann-La Roche AG Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
CA2807014A1 (en) 2010-08-03 2012-02-09 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
MX2013001267A (es) 2010-08-13 2013-04-10 Genentech Inc ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD.
TW201208703A (en) 2010-08-17 2012-03-01 Roche Glycart Ag Combination therapy of an afucosylated CD20 antibody with an anti-VEGF antibody
WO2012025530A1 (en) 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
CA2809433A1 (en) 2010-08-26 2012-03-01 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
CN103347514B (zh) 2010-11-15 2017-02-08 戊瑞治疗有限公司 Fgfr1胞外域组合疗法
EP2655413B1 (en) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
WO2012095514A1 (en) 2011-01-14 2012-07-19 Vivalis Recombinant protein production system
WO2012116927A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Monovalent antigen binding proteins
MX341921B (es) 2011-02-28 2016-09-07 Hoffmann La Roche Proteinas de union a antigeno.
CN103561771B (zh) 2011-03-17 2019-01-04 伯明翰大学 重新定向的免疫治疗
EP3590965A1 (en) 2011-03-29 2020-01-08 Roche Glycart AG Antibody fc variants
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
WO2012135759A1 (en) 2011-04-01 2012-10-04 Genentech, Inc. Combinations of akt inhibitor compounds and abiraterone, and methods of use
AU2012245439B2 (en) 2011-04-20 2017-04-06 Acceleron Pharma, Inc. Endoglin polypeptides and uses thereof
CA2834776A1 (en) 2011-05-03 2012-11-08 Genentech, Inc. Therapeutic apo2l/trail polypeptides and death receptor agonist antibodies
WO2012172054A1 (en) 2011-06-16 2012-12-20 Scil Proteins Gmbh Modified multimeric ubiquitin proteins binding vegf-a
WO2013003680A1 (en) 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations
EP2732269B1 (en) 2011-07-12 2017-10-18 Epitomics, Inc. Facs-based method for obtaining an antibody sequence
US9181532B2 (en) 2011-07-29 2015-11-10 Icon Genetics Gmbh Production of galactosylated N-glycans in plants
WO2013025944A1 (en) 2011-08-17 2013-02-21 Genentech, Inc. Inhibition of angiogenesis in refractory tumors
CN107722122B (zh) 2011-09-23 2022-05-27 昂考梅德药品有限公司 Vegf/dll4结合剂及其应用
US10196664B2 (en) 2011-10-04 2019-02-05 Icon Genetics Gmbh Nicotiana benthamiana plants deficient in fucosyltransferase activity
PT2766093T (pt) 2011-10-11 2018-05-18 Vaccinex Inc Utilização de moléculas de ligação a semaforina-4d para modulação da permeabilidade da barreira hematoencefálica
BR112014008759A8 (pt) * 2011-10-13 2017-09-12 Aerpio Therapeutics Inc Tratamento de doença ocular
US20130095065A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for Treating Vascular Leak Syndrome and Cancer
WO2013082511A1 (en) 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
CA2858347C (en) 2011-12-05 2020-07-07 Duke University V1v2 immunogens
US8790652B2 (en) 2011-12-06 2014-07-29 Vaccinex, Inc. Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis
RU2648999C2 (ru) 2011-12-22 2018-03-29 Дженентек, Инк. Способы повышения эффективности этапов очистки белка, находящихся ниже по потоку, с использованием мембранной ионообменной хроматографии
WO2013091903A1 (en) 2011-12-22 2013-06-27 Novo Nordisk A/S Anti-crac channel antibodies
BR112014015851A2 (pt) 2011-12-30 2019-09-24 Abbvie Inc proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17
BR112014017320A2 (pt) 2012-01-13 2018-05-29 Genentech Inc método para determinar se um paciente é propenso a responder ao tratamento com um antagonista de vegf, método para otimizar a eficácia terapêutica de um antagonista de vegf, método para selecionar uma terapia, método para identificar um biomarcador e método para diagnosticar um distúrbio angiogênico
RU2644341C2 (ru) 2012-02-10 2018-02-08 Дженентек, Инк. Одноцепочечные антитела и другие гетеромультимеры
WO2013127829A1 (en) 2012-02-27 2013-09-06 Universitat De Barcelona Protease-resistant compounds useful as shuttles through the blood-brain barrier and shuttle-cargo constructs
JP6563197B2 (ja) 2012-03-13 2019-08-21 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 卵巣癌の治療のための併用療法
MY171729A (en) 2012-03-27 2019-10-25 Genentech Inc Improved harvest operations for recombinant proteins
HK1200739A1 (en) 2012-03-30 2015-08-14 霍夫曼-拉罗奇有限公司 Diagnostic methods and compositions for treatment of cancer
ES2740749T3 (es) 2012-04-20 2020-02-06 Merus Nv Métodos y medios para la producción de moléculas heterodiméricas similares a Ig
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
WO2013170182A1 (en) 2012-05-11 2013-11-14 Synta Pharmaceuticals Corp. Treating cancer with an hsp90 inhibitory compound
EP2855528B1 (en) 2012-05-31 2019-06-19 Genentech, Inc. Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
AU2013269594C1 (en) 2012-06-01 2020-12-17 Novartis Ag Syringe
HK1202265A1 (en) 2012-06-08 2015-09-25 霍夫曼-拉罗奇有限公司 Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
CA2871880A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
RU2015100656A (ru) 2012-06-27 2016-08-20 Ф. Хоффманн-Ля Рош Аг Способ получения конъюгатов fc-фрагмента антитела, включающих по меньшей мере одну связывающую группировку, которая специфически связывается с мишенью, и их применения
JOP20200175A1 (ar) 2012-07-03 2017-06-16 Novartis Ag حقنة
US9695233B2 (en) 2012-07-13 2017-07-04 Roche Glycart Ag Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
BR112015002681A2 (pt) 2012-08-07 2018-08-28 Genentech Inc método para tratar um paciente e kit
HRP20190060T1 (hr) 2012-09-19 2019-02-22 F. Hoffmann - La Roche Ag Postupci i sastavi za sprečavanje pogrešne ugradnje norleukina u proteine
AU2013337811A1 (en) 2012-10-31 2015-05-14 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a DLL4 antagonist
BR112015009961B1 (pt) 2012-11-01 2020-10-20 Abbvie Inc. proteína de ligação capaz de se ligar a dll4 e vegf, bem como composição que a compreende como composição que a compreende
JP2016500058A (ja) 2012-11-12 2016-01-07 レッドウッド バイオサイエンス， インコーポレイテッド 化合物および抱合体を生成するための方法
US9310374B2 (en) 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
EP2920148B1 (en) 2012-11-16 2019-06-12 The Regents of the University of California Pictet-spengler ligation for protein chemical modification
MX2015007931A (es) 2012-12-18 2015-10-05 Novartis Ag Composiciones y metodos que utilizan una etiqueta de peptido que se une a hialuronano.
EP2934602B1 (en) 2012-12-19 2019-02-27 Genentech, Inc. Methods and compositions for radiohalogen protein labeling
WO2014110261A1 (en) 2013-01-11 2014-07-17 Massachusetts Eye And Ear Infirmary Cyp450 lipid metabolites reduce inflammation and angiogenesis
ES2774964T3 (es) 2013-02-04 2020-07-23 Vascular Biogenics Ltd Métodos para inducir la capacidad de respuesta a un agente antiangiogénico
CA2901226C (en) 2013-02-18 2020-11-17 Vegenics Pty Limited Vascular endothelial growth factor binding proteins
SG11201507475UA (en) 2013-03-13 2015-10-29 Genentech Inc Antibody formulations
JP2016513478A (ja) 2013-03-15 2016-05-16 ジェネンテック， インコーポレイテッド 細胞培養培地及び抗体を産生する方法
MX2015013166A (es) 2013-03-15 2015-12-11 Abbvie Inc Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17.
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
CN105164157B (zh) 2013-04-29 2024-05-28 豪夫迈·罗氏有限公司 Fc-受体结合的修饰的非对称抗体及使用方法
UA118029C2 (uk) 2013-04-29 2018-11-12 Ф. Хоффманн-Ля Рош Аг Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
AU2014268519A1 (en) 2013-05-23 2015-11-05 Five Prime Therapeutics, Inc. Methods of treating cancer
KR101541478B1 (ko) * 2013-05-31 2015-08-05 동아쏘시오홀딩스 주식회사 항-vegf 항체 및 이를 포함하는 암 또는 신생혈관형성관련 질환의 예방, 진단 또는 치료용 약학 조성물
ES2782834T3 (es) 2013-06-25 2020-09-16 Vaccinex Inc Uso de moléculas inhibidoras de semaforina-4D en combinación con una terapia inmunomoduladora para inhibir el crecimiento tumoral y la metástasis
SG11201510315TA (en) 2013-07-12 2016-01-28 Ophthotech Corp Methods for treating or preventing ophthalmological conditions
KR20180021234A (ko) 2013-08-12 2018-02-28 제넨테크, 인크. 보체-연관 상태의 치료를 위한 조성물 및 방법
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
WO2015035342A2 (en) 2013-09-08 2015-03-12 Oligasis Llc Factor viii zwitterionic polymer conjugates
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
KR20160044060A (ko) 2013-10-11 2016-04-22 에프. 호프만-라 로슈 아게 다중특이적 도메인 교환된 통상의 가변 경쇄 항체
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
CN105899225A (zh) 2013-10-25 2016-08-24 阿塞勒隆制药公司 用于治疗纤维化疾病的内皮联蛋白肽
ES2875878T3 (es) 2013-11-18 2021-11-11 Formycon Ag Composición farmacéutica de un anticuerpo anti-VEGF
US9493413B2 (en) 2013-11-27 2016-11-15 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
CN105263959A (zh) * 2013-12-31 2016-01-20 财团法人生物技术开发中心 抗vegf抗体及其用途
CN110981957B (zh) 2014-01-15 2024-12-24 豪夫迈·罗氏有限公司 具有改善的蛋白A结合作用的Fc区变体
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
AU2015217278B2 (en) 2014-02-14 2020-03-19 Macrogenics, Inc. Improved methods for the treatment of vascularizing cancers
EP3108255B1 (en) 2014-02-18 2020-08-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of diseases mediated by the nrp-1/obr complex signaling pathway
WO2015128795A1 (en) 2014-02-25 2015-09-03 Dr. Reddy's Laboratories Limited Process for modifying galactosylation and g0f content of a glycoprotein composition by glutamine supplementation
CN106103465B (zh) 2014-03-10 2021-01-08 吉瑞工厂 使用预清洗步骤的免疫球蛋白纯化
KR102442436B1 (ko) 2014-03-14 2022-09-15 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
CA2943329A1 (en) 2014-03-24 2015-10-01 Genentech, Inc. Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
MX2016012779A (es) 2014-03-31 2017-04-27 Genentech Inc Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40.
JP2017515811A (ja) 2014-05-01 2017-06-15 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体変異体及びその使用法
RU2702748C2 (ru) 2014-05-12 2019-10-11 Формикон Аг Предварительно заполненный пластиковый шприц, содержащий антагонист vegf
CA2949121A1 (en) 2014-05-15 2015-11-19 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
KR102557615B1 (ko) 2014-06-06 2023-07-20 레드우드 바이오사이언스 인코포레이티드 항-her2 항체-메이탄신 컨쥬게이트 및 이것의 사용 방법
WO2015198243A2 (en) 2014-06-25 2015-12-30 Novartis Ag Compositions and methods for long acting proteins
US20170327553A1 (en) 2014-06-25 2017-11-16 Novartis Ag Compositions and methods for long acting proteins
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
SI3166401T1 (sl) 2014-07-09 2020-11-30 F. Hoffmann-La Roche Ag Prilagoditev pH-vrednosti za okrevanje celičnih bank po odtajanju
CN106460067A (zh) 2014-07-14 2017-02-22 豪夫迈·罗氏有限公司 诊断方法和用于治疗成胶质细胞瘤的组合物
CN105330739B (zh) * 2014-08-12 2020-12-25 中美华世通生物医药科技（武汉）有限公司 与人血管内皮生长因子特异性结合的抗体或其抗原结合片段及其用途
EP3180018B1 (en) 2014-08-12 2019-07-24 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
US20170224777A1 (en) 2014-08-12 2017-08-10 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
JP6681905B2 (ja) 2014-09-13 2020-04-15 ノバルティス アーゲー Ａｌｋ阻害剤の併用療法
RU2704611C2 (ru) 2014-09-15 2019-10-30 Дженентек, Инк. Составы на основе антител
KR20170066546A (ko) 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EA201790834A1 (ru) 2014-10-14 2018-01-31 Новартис Аг Молекулы антител к pd-l1 и их применение
WO2016061562A2 (en) 2014-10-17 2016-04-21 Kodiak Sciences Inc. Butyrylcholinesterase zwitterionic polymer conjugates
US10316094B2 (en) 2014-10-24 2019-06-11 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for inducing phagocytosis of MHC class I positive cells and countering anti-CD47/SIRPA resistance
PT3212233T (pt) 2014-10-31 2020-07-16 Oncomed Pharm Inc Terapia combinada para o tratamento de doenças
EP3218403B1 (en) 2014-11-10 2020-05-13 F.Hoffmann-La Roche Ag Anti-interleukin-33 antibodies and uses thereof
EP3227332B1 (en) 2014-12-03 2019-11-06 F.Hoffmann-La Roche Ag Multispecific antibodies
CN112826934A (zh) 2014-12-11 2021-05-25 拜耳医药保健有限责任公司 具有小的活动性脉络膜新生血管病变的年龄相关性黄斑变性的治疗
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
HK1243141A1 (zh) 2014-12-23 2018-07-06 豪夫迈．罗氏有限公司 用於治疗和诊断化学疗法抗性癌症的组合物和方法
EP3250596A1 (en) * 2015-01-28 2017-12-06 Pfizer Inc Stable aqueous anti- vascular endothelial growth factor (vegf) antibody formulation
KR20220070057A (ko) 2015-03-09 2022-05-27 인테크린 테라퓨틱스, 아이엔씨. 비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법
CN115932273A (zh) 2015-04-24 2023-04-07 豪夫迈·罗氏有限公司 鉴定包含结合多肽的细菌的方法
US20180155429A1 (en) 2015-05-28 2018-06-07 Bristol-Myers Squibb Company Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
US11078278B2 (en) 2015-05-29 2021-08-03 Bristol-Myers Squibb Company Treatment of renal cell carcinoma
US20170000885A1 (en) 2015-06-08 2017-01-05 Genentech, Inc. Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
RS61532B1 (sr) 2015-07-14 2021-04-29 Bristol Myers Squibb Co Postupak lečenja kancera primenom inhibitora imunološke kontrolne tačke; antitelo koje se vezuje za receptor programirane smrti-1 (pd-1) ili ligand programirane smrti-1 (pd-l1)
JP6916776B2 (ja) 2015-07-29 2021-08-11 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｎｇ−２に対する重鎖のみ抗体
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
ES2878188T3 (es) 2015-07-29 2021-11-18 Novartis Ag Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
EP3316902A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to tim-3
HU231463B1 (hu) 2015-08-04 2024-01-28 Richter Gedeon Nyrt. Módszer rekombináns proteinek galaktóz tartalmának növelésére
EP3334762A1 (en) 2015-08-14 2018-06-20 Allergan, Inc. Heavy chain only antibodies to pdgf
WO2017034906A1 (en) * 2015-08-21 2017-03-02 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
IL257531B2 (en) 2015-09-17 2023-04-01 Immunogen Inc Medicinal compositions containing anti-folr1 immunoconjugates
WO2017046140A1 (en) 2015-09-18 2017-03-23 Bayer Pharma Aktiengesellschaft Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia
US10647752B2 (en) 2015-09-22 2020-05-12 Inserm (Institut National De La Santé Et De La Recherche Medicale) Polypeptides capable of inhibiting the binding between leptin and Neuropilin-1
RU2763916C2 (ru) 2015-09-23 2022-01-11 Дженентек, Инк. Оптимизированные варианты анти-vegf антител
ES2968074T3 (es) 2015-09-23 2024-05-07 Mereo Biopharma 5 Inc Anticuerpo bi-específico anti-VEGF/DLL4 para su uso en el tratamiento del cáncer de ovario resistente al platino
WO2017055325A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of nk cells in a tissue sample
WO2017055326A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of myeloid dendritic cells in a tissue sample
WO2017055324A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of cells of monocytic origin in a tissue sample
WO2017055319A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of b cells in a tissue sample
WO2017055322A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of neutrophils in a tissue sample
WO2017055321A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of fibroblasts in a tissue sample
WO2017055320A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of cytotoxic lymphocytes in a tissue sample
WO2017055327A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of endothelial cells in a tissue sample
WO2017064121A1 (en) 2015-10-13 2017-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
CN108289951A (zh) 2015-10-30 2018-07-17 豪夫迈·罗氏有限公司 抗-因子d抗体和缀合物
EP3368578B1 (en) 2015-10-30 2021-03-17 H. Hoffnabb-La Roche Ag Anti-htra1 antibodies and methods of use thereof
CN108472382A (zh) 2015-10-30 2018-08-31 豪夫迈·罗氏有限公司 抗-因子d抗体变体缀合物及其用途
AU2016344133A1 (en) 2015-10-30 2018-05-17 Genentech, Inc. Anti-Factor D antibody formulations
MA43186B1 (fr) 2015-11-03 2022-03-31 Janssen Biotech Inc Anticorps se liant spécifiquement à pd-1 et leurs utilisations
EP3370764A4 (en) 2015-11-05 2019-07-17 The Regents of The University of California Cells labeled with lipid conjugates and method of use thereof
JP6855496B2 (ja) 2015-11-09 2021-04-07 アール．ピー．シェーラー テクノロジーズ エルエルシー 抗ｃｄ２２抗体−メイタンシンコンジュゲートおよびその使用方法
EP3377151A1 (en) 2015-11-18 2018-09-26 Formycon AG Pre-filled plastic syringe containing a vegf antagonist
RU2734958C2 (ru) 2015-11-18 2020-10-26 Формикон Аг Предварительно заполненная фармацевтическая упаковка, содержащая жидкий состав на основе антагониста vegf
MX382662B (es) 2015-11-18 2025-03-11 Sio2 Medical Products Inc Envase farmacéutico para formulaciones oftálmicas.
DK3384049T3 (da) 2015-12-03 2023-10-02 Regeneron Pharma Fremgangsmåder til associering af genetiske varianter med et klinisk resultat hos patienter, der lider af aldersrelateret makuladegeneration behandlet med anti-VEGF
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
JP7088454B2 (ja) 2015-12-30 2022-06-21 コディアック サイエンシーズ インコーポレイテッド 抗体および抗体複合体
EP3407868A1 (en) 2016-01-26 2018-12-05 Formycon AG Liquid formulation of a vegf antagonist
CN109069638B (zh) 2016-03-24 2022-03-29 璟尚生物制药公司 用于癌症治疗的三特异性抑制剂
US10941406B2 (en) 2016-03-29 2021-03-09 Geltor, Inc. Expression of proteins in gram-negative bacteria wherein the ratio of periplasmic volume to cytoplasmic volume is between 0.5:1 and 10:1
KR20190003957A (ko) 2016-04-15 2019-01-10 제넨테크, 인크. 암 모니터링 및 치료 방법
WO2017181111A2 (en) 2016-04-15 2017-10-19 Genentech, Inc. Methods for monitoring and treating cancer
JP7169195B2 (ja) 2016-05-20 2022-11-10 バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッド 癌を処置するためのリルゾール、リルゾールプロドラッグまたはリルゾール類似体と免疫療法との併用
JP7050702B2 (ja) 2016-07-08 2022-04-08 ジェネンテック， インコーポレイテッド Ｎｒｆ２及びその遺伝子の下流標的遺伝子の発現状態及び変異状態によるがんの診断及び治療方法
TWI823836B (zh) 2016-07-08 2023-12-01 美商建南德克公司 人類副睪蛋白４（ｈｅ４）用於評定癌症治療反應性之用途
WO2018011166A2 (en) 2016-07-12 2018-01-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of myeloid dendritic cells in a tissue sample
US11613586B2 (en) 2016-07-15 2023-03-28 Takeda Pharmaceutical Company Limited Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies
SG11201900464TA (en) 2016-07-20 2019-02-27 Aerpio Therapeutics Inc HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
CN106222129A (zh) * 2016-07-29 2016-12-14 广东东阳光药业有限公司 一种提高抗体纯度的细胞培养基和培养方法
WO2018018613A1 (zh) 2016-07-29 2018-02-01 广东东阳光药业有限公司 一种提高抗体纯度的细胞培养基和培养方法
MX2019001635A (es) 2016-08-12 2019-06-10 Genentech Inc Terapia de combinacion con un inhibidor de mek, un inhibidor del eje de pd-1, y un inhibidor de vegf.
ES2836286T3 (es) * 2016-08-23 2021-06-24 Medimmune Ltd Anticuerpos anti-VEGF-A y usos de los mismos
JPWO2018070390A1 (ja) 2016-10-12 2019-08-22 第一三共株式会社 抗ｒｏｂｏ４抗体と他剤を含む組成物
CA3040179A1 (en) 2016-10-19 2018-04-26 Adverum Biotechnologies, Inc. Modified aav capsids and uses thereof
US10537637B2 (en) 2017-01-05 2020-01-21 Gensun Biopharma Inc. Checkpoint regulator antagonists
US10350266B2 (en) 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein
WO2018132516A1 (en) 2017-01-10 2018-07-19 Nodus Therapeutics Combination tumor treatment with an integrin-binding-fc fusion protein and immune modulator
AU2018228873A1 (en) 2017-03-01 2019-08-29 Genentech, Inc. Diagnostic and therapeutic methods for cancer
EP3601332A1 (en) * 2017-03-24 2020-02-05 Council of Scientific and Industrial Research A process for the purification of recombinant antibody fragments
SG11201909046XA (en) 2017-04-03 2019-10-30 Coherus Biosciences Inc PPARγ AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
KR102607655B1 (ko) 2017-05-19 2023-11-28 카운슬 오브 사이언티픽 앤드 인더스트리얼 리서치 리폴딩된 재조합 인간화 라니비주맙의 제조 방법
WO2018215580A1 (en) 2017-05-24 2018-11-29 Formycon Ag Method for sterilizing prefilled plastic syringes containing a vegf antagonist
US20200171244A1 (en) 2017-05-24 2020-06-04 Sio2 Medical Products, Inc. Sterilizable pharmaceutical package for ophthalmic formulations
US20200237997A1 (en) 2017-05-24 2020-07-30 Formycon Ag Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
TW201904610A (zh) 2017-06-14 2019-02-01 德商拜耳製藥公司 用於治療新生血管型青光眼之非抗體vegf拮抗劑
CN110785187B (zh) 2017-06-22 2024-04-05 诺华股份有限公司 针对cd73的抗体分子及其用途
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
EP3650045B1 (en) 2017-07-04 2024-11-13 Daiichi Sankyo Company, Limited Drug for retinal degenerative disease associated with photoreceptor degeneration
WO2019020777A1 (en) 2017-07-26 2019-01-31 Formycon Ag LIQUID FORMULATION OF A VEGF ANTAGONIST
WO2019057946A1 (en) 2017-09-25 2019-03-28 F. Hoffmann-La Roche Ag MULTI-CYCLIC AROMATIC COMPOUNDS AS D-FACTOR INHIBITORS
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
CN111356480A (zh) 2017-10-20 2020-06-30 脉管生物生长有限公司 用于抗血管生成剂疗法的诊断方法
MY207644A (en) 2017-12-19 2025-03-07 Akouos Inc Aav-mediated delivery of therapeutic antibodies to the inner ear
CN111511400B (zh) 2017-12-29 2025-08-29 豪夫迈·罗氏有限公司 抗vegf抗体及其使用方法
CN110003328B (zh) * 2018-01-05 2022-04-19 百奥泰生物制药股份有限公司 一种长效低毒的重组抗vegf人源化单克隆抗体及其生产方法
WO2019140410A1 (en) 2018-01-12 2019-07-18 Takeda Pharmaceutical Company Limited Subcutaneous dosing of anti-cd38 antibodies
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
CN111699004A (zh) 2018-02-06 2020-09-22 豪夫迈·罗氏有限公司 眼科疾病的治疗
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
CA3093468A1 (en) 2018-03-09 2019-09-12 Agenus Inc. Anti-cd73 antibodies and methods of use thereof
WO2019201195A1 (zh) 2018-04-16 2019-10-24 上海岸阔医药科技有限公司 预防或治疗肿瘤疗法副作用的方法
JP7235770B2 (ja) 2018-05-10 2023-03-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 高濃度ｖｅｇｆ受容体融合タンパク質を含む製剤
AU2019274657A1 (en) 2018-05-24 2020-12-10 Janssen Biotech, Inc. PSMA binding agents and uses thereof
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
WO2019229116A1 (en) 2018-05-31 2019-12-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Intravitreal delivery of a decorin polypeptide for the treatment of choroidal neovascularisation
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2020006516A1 (en) 2018-06-29 2020-01-02 Gensun Biopharma, Inc. Antitumor immune checkpoint regulator antagonists
MX2020013633A (es) 2018-07-03 2021-03-25 Bristol Myers Squibb Co Metodos para producir proteinas recombinantes.
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
CN109053895B (zh) 2018-08-30 2020-06-09 中山康方生物医药有限公司 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
EP3856245A4 (en) 2018-09-24 2022-10-26 EyePoint Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - ß (VE-PTP) AND VEGF
US12415980B2 (en) 2018-10-10 2025-09-16 Boehringer Ingelheim International Gmbh Method for membrane gas transfer in high density bioreactor culture
WO2020081767A1 (en) 2018-10-18 2020-04-23 Genentech, Inc. Diagnostic and therapeutic methods for sarcomatoid kidney cancer
HU231514B1 (hu) 2018-11-07 2024-07-28 Richter Gedeon Nyrt. Sejttenyészetben előállított rekombináns glikoprotein glikozilációs mintázatának megváltoztatására szolgáló módszer
WO2020109343A1 (en) 2018-11-29 2020-06-04 F. Hoffmann-La Roche Ag Combination therapy for treatment of macular degeneration
CN109134651B (zh) * 2018-12-03 2019-02-22 上海复宏汉霖生物技术股份有限公司 一种抗vegf的单克隆抗体及其制备方法和应用
US20200207812A1 (en) 2018-12-07 2020-07-02 Coherus Biosciences, Inc. Methods for producing recombinant proteins
AU2019402097A1 (en) 2018-12-17 2021-06-10 Revitope Limited Twin immune cell engager
CA3131936A1 (en) 2019-03-13 2020-09-17 Vascular Biogenics Ltd. Methods of anti-tumor therapy
AU2020254582B2 (en) 2019-04-01 2025-12-18 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
HU231498B1 (hu) 2019-04-04 2024-05-28 Richter Gedeon Nyrt Immunglobulinok affinitás kromatográfiájának fejlesztése kötést megelőző flokkulálás alkalmazásával
CN113993885B (zh) 2019-04-12 2025-04-25 格尔托公司 重组弹性蛋白及其生产
US11591395B2 (en) 2019-04-19 2023-02-28 Janssen Biotech, Inc. Methods of treating prostate cancer with an anti-PSMA/CD3 antibody
TWI862583B (zh) 2019-04-26 2024-11-21 美商愛德維仁生物科技公司 用於玻璃體內遞送之變異體aav蛋白殼
AU2020270376A1 (en) 2019-05-03 2021-10-07 Genentech, Inc. Methods of treating cancer with an anti-PD-L1 antibody
EP3965816A1 (en) 2019-05-06 2022-03-16 MedImmune Limited Combination of monalizumab, durvalumab, chemotherapy and bevacizumab or cetuximab for the treatment of colorectal cancer
US10851157B2 (en) 2019-07-01 2020-12-01 Gensun Biopharma, Inc. Antagonists targeting the TGF-β pathway
KR20220039777A (ko) 2019-08-01 2022-03-29 브리스톨-마이어스 스큅 컴퍼니 유가식 세포 배양에서 단백질 생산성을 개선시키는 방법
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021072182A1 (en) 2019-10-11 2021-04-15 Coherus Biosciences, Inc. Methods for producing ranibizumab
WO2021072210A1 (en) 2019-10-11 2021-04-15 Coherus Biosciences, Inc. Methods of purifying ranibizumab or a ranibizumab variant
JP7558272B2 (ja) 2019-11-19 2024-09-30 プロタリクス リミテッド 形質転換細胞からの構築物の除去
KR20220104033A (ko) 2019-11-25 2022-07-25 아케소 바이오파마, 인크. 항-pd-1-항-vegfa 이중특이항체, 약학 조성물 및 이의 용도
WO2021180818A1 (en) 2020-03-11 2021-09-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy
TW202144410A (zh) 2020-03-13 2021-12-01 美商建南德克公司 抗介白素－３３抗體及其用途
US12091681B2 (en) 2020-03-27 2024-09-17 Mendus B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
EP4127724A1 (en) 2020-04-03 2023-02-08 Genentech, Inc. Therapeutic and diagnostic methods for cancer
WO2022003568A1 (en) 2020-06-30 2022-01-06 Dcprime B.V. Use of leukemia-derived cells in ovarian cancer vaccines
MX2023000547A (es) 2020-07-16 2023-02-13 Novartis Ag Anticuerpos anti-betacelulina, fragmentos de los mismos, y moleculas de union multiespecificas.
CN114106190B (zh) * 2020-08-31 2025-04-08 普米斯生物技术(珠海)有限公司 一种抗vegf/pd-l1双特异性抗体及其用途
JP2023542924A (ja) 2020-09-22 2023-10-12 ブリストル－マイヤーズ スクイブ カンパニー 治療タンパク質を生産するための方法
KR20230113283A (ko) 2020-10-05 2023-07-28 프로탈릭스 리미티드 다이서-유사 넉아웃 식물 세포
EP4228706A1 (en) 2020-10-15 2023-08-23 Genentech, Inc. Hyaluronic acid binding derivatives of versican (vg1) for long acting delivery of therapeutics
IL301293A (en) 2020-11-13 2023-05-01 Genentech Inc Methods and compositions comprising a krasg12c inhibitor and a vegf inhibitor for treating solid tumors
CA3201005A1 (en) 2020-11-20 2022-05-27 R.P. Scherer Technologies, Llc Glycoside dual-cleavage linkers for antibody-drug conjugates
MX2023006451A (es) 2020-12-01 2023-06-15 Akouos Inc Construcciones de anticuerpos anti-vegf y metodos relacionados para el tratamiento de los sintomas asociados al schwannoma vestibular.
WO2022157715A1 (en) 2021-01-22 2022-07-28 Dcprime B.V. Methods of tumor vaccination
PE20240761A1 (es) 2021-01-28 2024-04-17 Janssen Biotech Inc Proteinas de union a psma y usos de estas
EP4304633A1 (en) 2021-03-12 2024-01-17 Mendus B.V. Methods of vaccination and use of cd47 blockade
KR20230156910A (ko) 2021-03-12 2023-11-15 아케소 바이오파마, 인크. 항-pd-1-항-vegfa 이중특이적 항체를 함유하는 약학적 조합 및 이의 용도
EP4329734A4 (en) 2021-04-26 2025-04-02 Celanese EVA Performance Polymers LLC Implantable device for the delayed release of a macromolecular drug compound
WO2022232503A1 (en) 2021-04-30 2022-11-03 Genentech, Inc. Therapeutic and diagnostic methods and compositions for cancer
JP2024519888A (ja) 2021-05-28 2024-05-21 上海瑞宏迪医薬有限公司 カプシド変異を有する組換えアデノ随伴ウイルス及びその応用
WO2022256820A1 (en) 2021-06-03 2022-12-08 Gensun Biopharma Inc. Multispecific antagonists
TW202309078A (zh) 2021-07-02 2023-03-01 美商建南德克公司 治療癌症之方法及組成物
CN117715936A (zh) 2021-07-28 2024-03-15 豪夫迈·罗氏有限公司 用于治疗癌症的方法和组合物
US20250115666A1 (en) 2021-08-05 2025-04-10 Bristol-Myers Squibb Company Cell culture methods for producing therapeutic proteins
CN118043350A (zh) 2021-08-13 2024-05-14 信达生物制药(苏州)有限公司 抗vegf a和vegf c双特异性抗体及其用途
EP4145456A1 (en) 2021-09-06 2023-03-08 Bayer AG Prediction of a change related to a macular fluid
US20240390869A1 (en) 2021-09-21 2024-11-28 Bristol-Myers Squibb Company Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container
WO2023080900A1 (en) 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
JPWO2023144973A1 (OSRAM) 2022-01-27 2023-08-03
KR20240144944A (ko) 2022-01-28 2024-10-04 온퀄리티 파마슈티컬스 차이나 리미티드 항종양제와 관련된 질병 또는 증상을 예방하거나 치료하는 방법
WO2023150142A1 (en) 2022-02-02 2023-08-10 Akouos, Inc. Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms
KR20240150493A (ko) 2022-02-21 2024-10-15 온퀄리티 파마슈티컬스 차이나 리미티드 화합물 및 그 용도
WO2024040175A1 (en) 2022-08-18 2024-02-22 Pulmatrix Operating Company, Inc. Methods for treating cancer using inhaled angiogenesis inhibitor
WO2024051223A1 (zh) 2022-09-09 2024-03-14 中山康方生物医药有限公司 药物组合及用途
WO2024186635A2 (en) 2023-03-03 2024-09-12 Celldex Therapeutics, Inc. Anti-stem cell factor (scf) and anti-thymic stromal lymphopoietin (tslp) antibodies and bispecific constructs
WO2024263904A1 (en) 2023-06-23 2024-12-26 Genentech, Inc. Methods for treatment of liver cancer
WO2024263195A1 (en) 2023-06-23 2024-12-26 Genentech, Inc. Methods for treatment of liver cancer
WO2025157267A1 (zh) * 2024-01-25 2025-07-31 中山康方生物医药有限公司 抗pd-1-抗vegfa的双特异性抗体的医药用途

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
JPS6289971A (ja) * 1985-06-13 1987-04-24 Toray Ind Inc 静電潜像用液体現像剤
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
CA2345497A1 (en) * 1988-10-28 1990-04-28 Genentech, Inc. Growth hormone variants and method for forming growth hormone variants
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5147638A (en) 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
ES2204890T3 (es) * 1991-03-06 2004-05-01 Merck Patent Gmbh Anticuerpos monoclonales humanizados.
DK1471142T3 (da) 1991-04-10 2009-03-09 Scripps Research Inst Heterodimere receptor-biblioteker under anvendelse af fagemider
CA2103059C (en) * 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
DK1136556T3 (da) 1991-11-25 2005-10-03 Enzon Inc Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner
JP3571337B2 (ja) 1992-02-11 2004-09-29 セル ジェネシス，インコーポレーテッド 遺伝子標的現象による同型遺伝子接合
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
WO1994010202A1 (en) * 1992-10-28 1994-05-11 Genentech, Inc. Vascular endothelial cell growth factor antagonists
DE69329503T2 (de) 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6037454A (en) * 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US20020032315A1 (en) * 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
SI1325932T1 (OSRAM) * 1997-04-07 2005-08-31 Genentech Inc
EP1695985B1 (en) * 1997-04-07 2011-03-09 Genentech, Inc. Methods for forming humanised antibodies by random mutagenesis

Also Published As

Publication number Publication date
LTPA2005005I1 (lt) 2017-11-27
FR07C0017I1 (fr) 2007-04-27
US7297334B2 (en) 2007-11-20
DE122005000050I1 (de) 2005-12-29
EP0973804A2 (en) 2000-01-26
JP2001509817A (ja) 2001-07-24
BR9809387A (pt) 2001-09-11
SI1325932T1 (OSRAM) 2005-08-31
EP1325932A2 (en) 2003-07-09
NL300193I2 (nl) 2005-10-03
EP1787999A1 (en) 2007-05-23
LU91320I2 (fr) 2007-04-30
DK0973804T3 (da) 2007-05-07
NO2007015I2 (OSRAM) 2011-11-28
GEP20105118B (en) 2010-11-25
NO2007014I2 (no) 2011-02-21
NO2007014I1 (no) 2008-01-14
NZ500078A (en) 2001-10-26
FR05C0020I1 (OSRAM) 2005-05-27
LU91320I9 (OSRAM) 2018-12-31
KR20080003453A (ko) 2008-01-07
EP1650220A2 (en) 2006-04-26
NO994869D0 (no) 1999-10-06
ATE293640T1 (de) 2005-05-15
BRPI9809387B1 (pt) 2016-11-22
US20050112126A1 (en) 2005-05-26
EP1325932A3 (en) 2003-10-29
AU743758B2 (en) 2002-02-07
HK1084402A1 (en) 2006-07-28
EP1787999B1 (en) 2010-08-04
EP1325932B9 (en) 2006-07-19
JP3957765B2 (ja) 2007-08-15
KR100870353B1 (ko) 2008-11-25
FR07C0017I2 (fr) 2008-05-09
CY2005008I1 (el) 2009-11-04
NL300193I1 (nl) 2005-07-01
BRPI9809387B8 (pt) 2021-05-25
DK1325932T5 (da) 2005-10-03
EP1325932B1 (en) 2005-04-20
EP1650220B1 (en) 2007-09-05
LU91167I2 (fr) 2005-06-20
CY2007012I2 (el) 2009-11-04
ATE349470T1 (de) 2007-01-15
HK1023577A1 (en) 2000-09-15
CA2286330A1 (en) 1998-10-15
NL300278I1 (nl) 2007-06-01
NL300278I2 (nl) 2007-10-01
EP1650220A3 (en) 2006-05-03
CA2286330C (en) 2008-06-10
NO994869L (no) 1999-12-06
PT1325932E (pt) 2005-06-30
FR05C0020I2 (fr) 2008-05-09
ES2236634T3 (es) 2005-07-16
KR20080003452A (ko) 2008-01-07
DE69836729D1 (de) 2007-02-08
DE69829891D1 (de) 2005-05-25
AU7100798A (en) 1998-10-30
CY2007012I1 (el) 2009-11-04
ES2273415T3 (es) 2007-05-01
NO2007015I1 (no) 2008-01-14
TR199903123T2 (xx) 2000-05-22
DE69836729T2 (de) 2007-12-13
DE122007000021I1 (de) 2007-05-24
WO1998045331A2 (en) 1998-10-15
NO324264B1 (no) 2007-09-17
DE122005000026I1 (de) 2005-08-04
WO1998045331A3 (en) 1998-12-03
KR100816621B1 (ko) 2008-03-24
US7060269B1 (en) 2006-06-13
DK1325932T3 (da) 2005-05-30
CN1259962A (zh) 2000-07-12
CY1106382T1 (el) 2010-07-28
CY2005008I2 (el) 2017-11-14
DE69829891T2 (de) 2005-10-06
CN100480269C (zh) 2009-04-22
EP0973804B1 (en) 2006-12-27

Similar Documents

Publication Publication Date Title
NO2019045I1 (no) Ranibizumab - Forlenget SPC
IL132240A0 (en) Anti-vegf antibodies

Legal Events

Date Code Title Description
EXTN Extension order renewed
FF Patent granted
KB Patent renewed
KB Patent renewed